FDA reviews Boehringer's Spiriva HandiHaler for stroke risk

The FDA announced Tuesday that it is conducting a safety review of Boehringer Ingelheim's Spiriva HandiHaler, a treatment for chronic obstructive pulmonary disease, after the company reported that it may increase the risk of stroke. The agency has asked the company to submit more data on the inhaler but warned patients against discontinuing treatment without proper medical advice.

View Full Article in:

Washington Post, The · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA